rheumatologists

lab test

Pirfenidone Delays PAH Progression in Rodent Model

Pirfenidone improves pulmonary hemodynamics and vascular remodeling in a rat model of pulmonary arterial hypertension (PAH), a new study published in Pulmonary Circulation found. The study also found that the treatment decreased the cleavage of IL-1β and IL-18, which are products of the activation of NLRP3 inflammasome and play key roles downstream from NLRP3. The…

cardiac catheterization

Study Highlights Noninvasive Approaches to Managing PAH

For patients with stable, low-risk cases of pulmonary arterial hypertension (PAH), current noninvasive approaches to risk stratification and disease management may be useful and more feasible than invasive right heart catheterization (RHC), according to a new study published in Expert Review of Cardiovascular Therapy. The researchers discuss the most appropriate timing for RHC and when…

machine learning

Machine Learning Uncovers Biomarkers in MG and Other Neurological Diseases

Machine learning analysis and genome-wide association studies (GWAS) identified biomarkers for the identification of several neurological diseases including myasthenia gravis (MG), as published in Frontiers in Molecular Neuroscience. The researchers identified a number of predictors of disease as well as genetic predispositions for the different neurological diseases including MG, Alzheimer’s disease, Parkinson’s disease, and motor…

microRNA

Study Provides Novel Insights Into Myasthenia Gravis Pathophysiology

The long noncoding RNA (lncRNA) growth arrest specific 5 (GAS5) can regulate the balance of T helper 17 (Th17)/regulatory T (Treg) cells in myasthenia gravis by targeting miR-23a expression, according to a new study published in the Journal of International Medical Research.  This finding provides a scientific basis for the development of clinical therapeutics for…

connective tissue

Study Supports Use of Immunosuppressive Therapy for CTD-PAH

Researchers reported that existing evidence supports the use of immunosuppressive therapeutics in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH), especially in systemic lupus erythematosus-associated PAH (SLE-PAH), as published in the International Journal of Rheumatic Disease. PAH is primarily characterized by pulmonary vascular remodeling which increases pulmonary vascular resistance. The current thinking when it comes…

pregnant woman with nurse

Researchers Report Full-Term, Healthy Neonates in Women With PAH

Researchers reported 7 out of 9 successful pregnancies and deliveries in a cohort of women with pulmonary arterial hypertension (PAH), as published in the Australian and New Zealand Journal of Obstetrics and Gynaecology. They noted that regional neuraxial anesthesia facilitated the delivery process and improved the patient experience. “The aim of this retrospective review was…

cardiopulmonary system

Inhaled Seralutinib Effectively Treats Animal Models With Severe PAH

Inhaled seralutinib improved cardiopulmonary hemodynamics and inflammatory biomarkers, reduced N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, and reversed remodeling of the pulmonary vasculature in 2 animal models of pulmonary arterial hypertension (PAH). The treatment was found to be more effective than imatinib. These results were published in the European Respiratory Journal. “We are excited to…

anemia

Sutimlimab May Decrease Hemolysis, Anemia, and Fatigue in Patients With CAD

A new study has demonstrated that sutimlimab, a humanized immunoglobulin G4 (IgG4) monoclonal antibody, was effective at halting hemolysis in recently transfused patients with cold agglutinin disease (CAD). The study, published in Blood, derived from the CADENZA study, a placebo-controlled trial of sutimlimab in patients with CAD from the CARDINAL study. “Sutimlimab has a novel…

Next post in CAD News Briefs